Citation: | LIN Xiaojun, CHEN Qin, DUAN Wenhua, ZHU Qin, HU Min. Clinical study of intermittent use of 1% atropine on retardation of myopia progression in Chinese school children[J]. CHINESE JOURNAL OF SCHOOL HEALTH, 2021, 42(2): 177-180. doi: 10.16835/j.cnki.1000-9817.2021.02.005 |
[1] |
LI Y, LIU J, QI P. The increasing prevalence of myopia in junior high school students in the Haidian District of Beijing, China: a 10-year population-based survey[J]. BMC Ophthalmol, 2017, 17(1): 88. doi: 10.1186/s12886-017-0483-6/open-peer-review
|
[2] |
XIANG F, HE M, ZENG Y, et al. Increases in the prevalence of reduced visual acuity and myopia in Chinese children in Guangzhou over the past 20 years[J]. Eye(Lond), 2013, 27(12): 1353-1358. http://www.ncbi.nlm.nih.gov/pubmed/24008929
|
[3] |
CHEN M, WU A, ZHANG L, et al. The increasing prevalence of myopia and high myopia among high school students in Fenghua city, eastern China: a 15-year population-based survey[J]. BMC Ophthalmol, 2018, 18(1): 159. doi: 10.1186/s12886-018-0829-8
|
[4] |
RADA J A, SHELTON S, NORTON T T. The sclera and myopia[J]. Exp Eye Res, 2006, 82: 185-200. DOI: 10.1016/j.exer.2005.08.009.
|
[5] |
SAW S M, GAZZARD G, SHIH-YEN E C, et al. Myopia and associated pathological complications[J]. Ophthal Physiol Opt, 2005, 25: 381-391. DOI: 10.1111/j.1475-1313.2005.00298.x.
|
[6] |
SAW S M. How blinding is pathological myopia?[J]. Br J Ophthalmol, 2006, 90: 525-526. DOI: 10.1136/bjo.2005.087999.
|
[7] |
TANO Y. Pathologic myopia: where are we now?[J]. Am J Ophthalmol, 2002, 134: 645-660. DOI: 10.1016/s0002-9394(02)01883-4.
|
[8] |
LIANG C L, YEN E, SU J Y, et al. Impact of family history of high myopia on level and onset of myopia[J]. Invest Ophthalmol Vis Sci, 2004, 45: 3446-3452. DOI: 10.1167/iovs.03-1058.
|
[9] |
THORN F, GWIAZDA J, HELD R. Myopia progression is specified by a double exponential growth function[J]. Optom Vis Sci, 2005, 82: 286-297. DOI: 10.1097/01.opx.0000159370.66540.34.
|
[10] |
LAM C S, EDWARDS M, MILLODOT M, et al. A 2-year longitudinal study of myopia progression and optical component changes among HongKong schoolchildren[J]. Optom Vis Sci, 1999, 76: 370-380. DOI: 10.1097/00006324-199906000-00016.
|
[11] |
CHUA S Y, IKRAM M K, TAN C S, et al. Relative contribution of risk factors for early-onset myopia in young asian children[J]. Invest Ophthalmol Vis Sci, 2015, 56: 8101-8107. DOI: 10.1167/iovs.15-16577.
|
[12] |
SHIH K C, CHAN T C, NG A L, et al. Use of atropine for prevention of childhood myopia progression in clinical practice[J]. Eye Contact Lens, 2016, 42: 16-23. DOI: 10.1097/ICL.0000000000000189.
|
[13] |
TIDEMAN J W L, POLLING J R, VINGERLING J R, et al. Axial length growth and the risk of developing myopia in European children[J]. Acta Ophthalmol, 2018, 96: 301-309. DOI: 10.1111/aos.13603.
|
[14] |
GWIAZDA J, HYMAN L, HUSSEIN M, et al. A randomized clinical trial of progressive addition lenses versus single vision lenses on the progression of myopia in children[J]. Invest Ophthalmol Vis Sci, 2003, 44: 1492-1500. DOI: 10.1167/iovs.02-0816.
|
[15] |
HASEBE S, OHTSUKI H, NONAKA T, et al. Effect of progressive addition lenses on myopia progression in Japanese children: a prospective, randomized, double-masked, crossover trial[J]. Invest Ophthalmol Vis Sci, 2008, 49: 2781-2789. DOI: 10.1167/iovs.07-0385.
|
[16] |
BERNTSEN D A, SINNOTT L T, MUTTI D O, et al. A randomized trial using progressive addition lenses to evaluate theories of myopia progression in children with a high lag of accommodation[J]. Invest Ophthalmol Vis Sci, 2012, 53: 640-649. DOI: 10.1167/iovs.11-7769.
|
[17] |
WALLINE J J, LINDSLEY K, VEDULA S S, et al. Interventions to slow progression of myopia in children[J]. Cochrane Database Syst Rev, 2011: CD004916. DOI: 10.1002/14651858.CD004916.pub3.
|
[18] |
CHO P, CHEUNG S W. Retardation of myopia in Orthokeratology (ROMIO) study: a 2-year randomized clinical trial[J]. Invest Ophthalmol Vis Sci, 2012, 53: 7077-7085. DOI: 10.1167/iovs.12-10565.
|
[19] |
SUN Y, XU F, ZHANG T, et al. Orthokeratology to control myopia progression: a meta-analysis[J]. PLoS One, 2015, 10: e0124535. DOI: 10.1371/journal.pone.0124535.
|
[20] |
KANG P, MCALINDEN C, WILDSOET C F. Effects of multifocal soft contact lenses used to slow myopia progression on quality of vision in young adults[J]. Acta Ophthalmol, 2017, 95: e43-e53. DOI: 10.1111/aos.13173.
|
[21] |
XIONG S, SANKARIDURG P, NADUVILATH T, et al. Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review[J]. Acta Ophthalmol, 2017, 95: 551-566. DOI: 10.1111/aos.13403.
|
[22] |
SAW S M. A synopsis of the prevalence rates and environmental risk factors for myopia[J]. Clin Exp Optom, 2003, 86: 289-294. DOI: 10.1111/j.1444-0938.2003.tb03124.x.
|
[23] |
SHIH Y F, CHEN C H, CHOU A C, et al. Effects of different concentrations of atropine on controlling myopia in myopic children[J]. J Ocul Pharmacol Ther, 1999, 15: 85-90. DOI: 10.1089/jop.1999.15.85.
|
[24] |
GWIAZDA J. Treatment options for myopia[J]. Optom Vis Sci, 2009, 86: 624-628. DOI: 10.1097/OPX.0b013e3181a6a225.
|
[25] |
MCBRIEN N A, STELL W K, CARR B. How does atropine exert its anti-myopia effects?[J]. Ophthal Physiol Opt, 2013, 33: 373-378. DOI: 10.1111/opo.12052.
|
[26] |
CHUA W H, BALAKRISHNAN V, CHAN Y H, et al. Atropine for the treatment of childhood myopia[J]. Ophthalmology, 2006, 113: 2285-2291. DOI: 10.1016/j.ophtha.2006.05.062.
|
[27] |
CHIA A, CHUA W H, CHEUNG Y B, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses(Atropine for the Treatment of Myopia 2)[J]. Ophthalmology, 2012, 119: 347-354. DOI: 10.1016/j.ophtha.2011.07.031.
|
[28] |
CHIA A, CHUA W H, WEN L, et al. Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%[J]. Am J Ophthalmol, 2014, 157: 451-457. DOI: 10.1016/j.ajo.2013.09.020.
|